Companies ›Healthcare ›4724.TWO

4724.TWO — TPEx Healthcare Facilities & Services

Meribank Biotech Co Ltd

$13,05

Open in Charts → Attach watcher ⌖

— —

TWD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

1,3B TWD

P/E

—

EV / Rev

—

Div yield

0,00 %

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Meribank Biotech Co Ltd is a biotechnology company engaged in the development and provision of healthcare services and equipment.

Business. Meribank Biotech Co Ltd (4724.TWO) is a biotechnology company operating within the Healthcare Facilities & Services industry. The firm is headquartered in Taiwan and is primarily listed on the Taiwan Premium Exchange (TPEx). Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryHealthcare Facilities & Services

ActivityBiotechnology

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 4724.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 4724.TWO. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Meribank Biotech Co Ltd (4724.TWO) is a biotechnology company operating within the Healthcare Facilities & Services industry. The firm is headquartered in Taiwan and is primarily listed on the Taiwan Premium Exchange (TPEx). Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryHealthcare Facilities & Services

ActivityBiotechnology

AI synthesis

GENERATED

Meribank Biotech has a market capitalization of TWD 1,290,877,200, with a market price of TWD 13.45 per share. The company has 95,976,000 basic and diluted shares outstanding, indicating no immediate dilution pressure from share issuance.

Profitability and return metrics are not available for Meribank Biotech due to the absence of detailed financial data in the provided sources. Without access to key performance indicators such as return on invested capital (ROIC) or operating margins, a direct comparison to industry medians cannot be made.

The company's revenue concentration and geographic exposure are not disclosed in the available data. As a result, the extent of its reliance on specific segments or regions remains unclear.

Growth trajectory data is limited, with no specific revenue growth rates or outlook figures provided in the available sources. The absence of forward-looking guidance or historical revenue trends prevents a detailed assessment of Meribank Biotech's growth potential.

Risk factors include an inability to assess liquidity risk due to the lack of balance-sheet inputs and no going-concern language in source documents. The company is currently flagged for liquidity risk, but the severity cannot be quantified.

Recent events and filings are not detailed in the available data, so no specific corporate actions or disclosures can be reported at this time.

Key takeaways

Meribank Biotech operates in the biotechnology segment of the healthcare industry.
The company has no immediate dilution pressure as basic and diluted shares are equal.
Liquidity risk cannot be assessed due to missing balance-sheet data.
Growth and profitability metrics are not available for comparison to industry benchmarks.
Revenue concentration and geographic exposure are not disclosed in the available data.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation FY

Market price

$13,05

Market cap

$1.29B

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

Meribank Biotech Co Ltd Market data — financials · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

4724.TWOCanonical

TPEx · TWD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread